Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development

Reuters

06-02

Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development

Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2540674367"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540674367\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2540674367?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-02 19:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540674367","market":"us","top_or_hot":-1,"title":"Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-06-02 19:24</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250602:nNDL8DrjnQ:1","article_id":"2540674367","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540674367","pubTimestamp":1748863469,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. Wh","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"翰森制药与再生元签署8000万美元药物开发许可协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":0.9,"REGN":0.9},"content_text":"Hansoh Pharmaceutical Signs $80 Million License Agreement with Regeneron for Drug Development\n    \n\n        Hansoh Pharmaceutical Group Company Limited has announced a significant licensing agreement with Regeneron Pharmaceuticals, Inc. The agreement grants Regeneron an exclusive worldwide license, excluding the Chinese Mainland, Hong Kong, and Macau, to develop, manufacture, and commercialize HS-20094, an investigational dual GLP-1/GIP receptor agonist. The licensure will see Hansoh receiving an upfront payment of $80 million, with the potential for up to $1.93 billion in milestone payments tied to the product's development, regulatory approval, and commercialization. Additionally, Hansoh will earn double-digit royalties from potential future product sales. HS-20094 has completed multiple Phase II trials with positive results and is currently undergoing a Phase III clinical trial in China. This collaboration marks a strategic advancement for both companies in the biotechnology sector.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hansoh Pharmaceutical Group Co. Ltd. published the original content used to generate this news brief on June 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}